Doctorate in Business Administration (DBA) from Paris School of Business

One of China's 30 Most Influential Investors, Honorary President of the Hong Kong Association of Pharmaceutical Innovation, Founding Member of the Investment Committee of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), Member of the BayHelix Group, and Distinguished Lecturer at Duke Kunshan University.

With over a decade of experience in the investment industry, he has focused on the biopharmaceutical sector, contributing to the advancement of the pharmaceutical industry. He has led investments in Heyuan Biosciences, Chipscreen Biosciences, Ascentage Pharma, Frontier Biotechnologies, Genuine Biotech, Qyuns Therapeutics, and others.

His accolades include:

• CHC · Top 50 Most Influential Investors of the Year

• FOF Weekly · Top 20 Best Healthcare Investors of 2023

• CHC · Top 50 Most Influential Investors of 2022

• ChinaVenture · Top 100 Chinese Best Venture Capitalists of 2021

• Best Investor in the Medical and Health Industry 2020

• China Financial Person of the Year Top 5 2019

Ph.D. and Postdoctoral Fellow in Materials Science, University of Nottingham, UK

Focuses on research and investment in medical devices, new energy, and advanced materials

With 7 years of investment experience, has led multiple industrial investment, M&A, and buyout projects

Pharmacy Doctor, Fudan University,

Research and investment in the field of anti-tumor drugs,

Experiences in consulting and healthcare investment,

Overseas mergers and acquisitions & innovative drug investment

• Bachelor of Arts in Economics, University of California, San Diego (UCSD)

• Member of the Inaugural Cohort of Young Investors of H50 (China Healthcare Investment H50)
  2023 Forbes China · Top 100 Young Returnee Elites
  2025 Fortune China · 40 Under 40 – Most Promising Business Elites
  Consecutive Honoree, U40 Young Elite List
  40 Under 40 – Best Direct Investment Fund Young Investors
  2022 Supernova · Top 50
  Young Investor in Healthcare

• Initiated and deeply participated in investments in star projects including OBiO Technology, Asieris Pharmaceuticals, Insight Lifetech, and Harbour BioMed

• Previously served in the Asset Management Department of China International Capital Corporation (CICC)

• Ph.D., Zhejiang University; Postdoctoral Fellow, Baylor College of Medicine; Adjunct Professor, Zhejiang University School of Medicine

• Principal Investigator (PI) at an independent laboratory in the United States; Supervisor for doctoral students and postdoctoral fellows; Recipient of multiple research grants, including the R01 grant from the National Institutes of Health (NIH)

• A decade of experience in the pharmaceutical industry; previously worked at Lexicon Pharmaceuticals (USA), Hisun Pharma, and others; contributed to the market approval or clinical trial advancement of multiple products

• Former Partner at Yingke Capital; full-spectrum coverage of pharmaceuticals, medical devices, IVD, and CXO; invested in over 30 portfolio companies

MSc of Biology, Sun Yat-Sen University, Focuses on gene, cell therapy, high-end medical device research and investment, many years of VC/PE investment experience, with > 15 successful investment cases, including 5 IPO projects

With over a decade of experience in financial management and capital operations across listed companies (Kingdee International, Wiscom System) and private equity funds. Holds a Bachelor's degree in Accounting. Deeply involved in investor relations, brand strategy, and post-investment exit management of core projects, driving diversified financing strategies and maximizing project value realization.

• M.D., Beijing Medical University; Ph.D., Jichi Medical University, Japan

• Former Director of the Chinese Center for Disease Control and Prevention; Deputy Director of China National Center for Biotechnology Development; Deputy Dean of Peking University Health Science Center

• Led major national science and technology programs including the "863 Program" and "973 Program"

Master's degree in Investment from Central University of Finance and Economics, and serves as an off-campus graduate advisor. Over ten years of experience in biomedical investment, with backgrounds in the investment department of a listed pharmaceutical company and a central SOE private equity firm. Has led investments and incubations in over 20 projects across innovative drugs and medical devices, with more than 6 exits through IPOs, M&A, and equity transfers. Has initiated and established multiple healthcare funds.

Bachelor's degree in Pharmacy from Shanghai Jiao Tong University and Master's degree in Finance from Durham University, UK, with a multidisciplinary background. Five years of investment experience, specializing in medical devices and new materials. Successfully exited 4 investments, including 2 IPO projects.

Ph.D. in Chemistry from the University of Texas at Austin. Nearly ten years of experience in biomedical investment in both China and the United States. Specializes in investments in cutting-edge biotechnology fields such as innovative drugs and synthetic biology.